^
Association details:
| Biomarker: | BRCA2 deletion |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | prexasertib (ACR-368) (Chk2 inhibitor, Chk1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Inhibiting Checkpoint Kinases Overcome PARPi Resistance in Prostate Cancer Cells
Published date:
10/09/2020
Excerpt:
We used human CRPC cell lines PC-3 and LNCaP-ABL (both harbor genomic deletion of BRCA2)....Treatment with a CHEK 1/2 inhibitor (CHEKi), prexasertib, led to cell growth inhibition in TALA-resistant PC-3 cells compared to parental PC-3 cells...Treatment of parental PC-3 and 22RV1 with combinations of TALA and varying conc. of prexasertib showed cell growth inhibition.
